surmount-1 trial tirzepatide non-diabetic weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers SURMOUNT-1: Tirzepatide Drastically Reduces Weight

Our program is designed for adults who want medically supervised weight loss with proper testing, monitoring, and support throughout the process

If refilled later than 45 days, pricing reverts to the standard (higher) cost

Industry standard : Most research peptide suppliers use 5mg as base size

Alonso Martin and the staff at BODYWELLE in Miami Beach, FL, know how important it is to manage weight well

Focus on protocol optimization before considering dose changes

It supports tissue repair, inflammation modulation, and regenerative signaling across muscles, tendons, ligaments, and the gut lining, making it a focus for research in angiogenesis research, injury tissue